ZIM
SAGE

Zacks Investment Management’s Sage Therapeutics SAGE Stock Holding History

Zacks Investment Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-4,399
Closed -$421K – 587
2018
Q4 		$421K Sell
4,399
-472
-10% -$54K 0.01% 451
2018
Q3 		$688K Buy
+4,871
New +$752K 0.01% 431

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Zacks Investment Management's SAGE Position: Q1 2019 in Review

Zacks Investment Management sold out of Sage Therapeutics (SAGE) in Q1 2019, closing a stake of 4,399 shares — an estimated $421K sold.

Zacks Investment Management first reported a position in SAGE in Q3 2018 and held it in 2 quarters. The position peaked at $688K in Q3 2018. 267 funds tracked by Wall St. Rank hold SAGE as of Q1 2019.

  • Zacks Investment Management reported no remaining Sage Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Zacks Investment Management sold 4,399 Sage Therapeutics shares in Q1 2019, an estimated $421K.
  • Zacks Investment Management first reported a position in Sage Therapeutics in Q3 2018 and held it in 2 quarters.
  • Zacks Investment Management's Sage Therapeutics position peaked at $688K in Q3 2018.
  • 267 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2019.

Based on Zacks Investment Management's 13F filing for Q1 2019, filed 15 May 2019.